BiologicalDrug
Peptides clinical trials
- studies test it
- 7
- open now
- 1
- in phase 3
- 0
- first study started
- 2008
Keep track of what changes. Save the Peptides studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
7 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 6
Adilia Hormigo (1) · Patrick Ott, MD, PhD (1) · Egymedicalpedia (1) · Nina Bhardwaj (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Ryazan State Medical University (1) · University of Yamanashi (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Peptides is read from its arms, and is right about nine times in ten.
Testing it · 7
- Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.RecruitingNot applicableRyazan State Medical UniversityNCT05933720Written as Polypeptides
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingPhase 1Adilia HormigoNCT03223103Written as Peptides
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedPhase 1Patrick Ott, MD, PhDNCT01970358Written as Peptides
- Evaluation of the Effect of Self-Assembling Peptide P11-4CompletedPhase 1EgymedicalpediaNCT05667545Written as Peptide
- Safety and Immunogenicity of Personalized Genomic Vaccine to Treat MalignanciesCompletedPhase 1Nina BhardwajNCT02721043Written as Peptides
- Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100CompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01008527Written as Peptides
- A Study With Peptide Vaccination in Treating Patients With Esophageal CancerStatus unknownPhase 2University of YamanashiNCT00995358Written as peptide
Given in every arm · 2 — Peptides is usual care beside what is tested
- Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01176474Written as gp100:280-288 (288V)
- A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in MelanomaStatus unknownPhase 1Xiangya Hospital of Central South UniversityNCT04072900Written as Peptide